Emergency management of immune-related toxicity
| dc.contributor.author | Cooksley, Timothy J | |
| dc.contributor.author | Stutman, R | |
| dc.contributor.author | Klotz, A | |
| dc.date.accessioned | 2020-08-10T08:09:18Z | |
| dc.date.available | 2020-08-10T08:09:18Z | |
| dc.date.issued | 2020 | en |
| dc.identifier.citation | Cooksley T, Stutman R, Klotz A. Emergency management of immune-related toxicity. Curr Opin Oncol. 2020;32(4):274-81. | en |
| dc.identifier.pmid | 32541313 | en |
| dc.identifier.doi | 10.1097/cco.0000000000000635 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/623079 | |
| dc.description.abstract | Purpose of review: Emergency presentations in patients treated with immune checkpoint inhibitors (ICIs) are a clinical challenge. Clinicians need to be vigilant in diagnosing and treating immune-mediated toxicities. In this review, we consider the approach to managing an acutely unwell patient being treated with ICIs presenting as an emergency. Recent findings: A minority of acutely unwell patients treated with ICIs will have an immune-mediated toxicity. Early recognition and intervention in those with immune-mediated toxicity can reduce the duration and severity of the complications. The use of early immunosuppressive agents along corticosteroid therapy may improve outcomes in patients with life-threatening immune-mediated toxicity. Summary: Individualized management of immune-mediated toxicities is a key challenge for emergency oncology services; this has become part of routine cancer care. | en |
| dc.language.iso | en | en |
| dc.relation.url | https://dx.doi.org/10.1097/cco.0000000000000635 | en |
| dc.title | Emergency management of immune-related toxicity | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Acute Medicine and Critical Care, The Christie, Manchester, UK. | en |
| dc.identifier.journal | Current Opinion in Oncology | en |
| dc.description.note | en] |